Key facts
| Company | Lus Essentials LLC |
|---|---|
| FDA office | Center for Drug Evaluation and Research (CDER) |
| Letter date | May 14, 2026 |
| Subject / product | Unapproved New Drugs/Misbranded |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | lus-essentials-llc-728783-05142026 |
Violations explained
FDA Warning Letter — Violations FDA cited at Lus Essentials LLC
WARNING LETTER Lus Essentials LLC MARCS-CMS 728783 — May 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 728783 Product: Drugs Recipient: Lus Essentials LLC 605 Ravoux Road Chaska , MN 55318 United States ningdeleon482@gmail.com info@lusessentials.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States May 14, 2026 WARNING LETTER To Lu’s Essentials: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA has observed that you offer products marketed on your firm’s website as skin treatment and skin lightening products, including, but not limited to, “Dr. Yanhee Acne Treatment Set (Green)” and “Dr. Yanhee Cream Set (Pekas & Melasma Treatment) – Blue” (hereinafter “your products”) for sale in the United States. Additionally, FDA obtained a sample of these products and has serious safety concerns about them. FDA confirmed through laboratory analysis that these products contain high levels of mercury. Applying products that contain mercury to the skin repeatedly can allow mercury to be absorbed into the bloodstream, potentially causing serious and permanent health problems, including kidney damage and neurological damage. Children and pregnant individuals face heightened risks and should avoid exposure to these products. FDA Review Violations were identified and documented during a review of your website https://lusessentials.store in April 2026. Based on our review, your products are unapproved new drugs and misbranded drugs under sections 505(a) and 502(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 352(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(a), 301(d), and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), and 355(a). This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act Unapproved New Drug Violations The following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations. Based on a review of your website, your products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: Dr. Yanhee Acne Treatment Set (Green) On the webpage https://lusessentials.store/products/dr-yanhee-acne-treatment-setgreen?variant=45027938828483: “Reduce acne, freckles, dark spots and tighten pores.” “Benefits: [t]reatment for [p]imples and [s]ever [sic] acne problems, [d]ark spots, reduce visible scars.” “Protects skin from the sun and skin whitening.” Dr. Yanhee Cream Set (Pekas & Melasma Treatment) - Blue On the webpage https://lusessentials.store/products/dr-yanhe
What happens next
Lus Essentials LLC is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
Lus Essentials LLC’s FDA history
Argus HQ has recorded 1 total FDA action tied to Lus Essentials LLC: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- Which FDA office issued the warning letter to Lus Essentials LLC?
- Center for Drug Evaluation and Research (CDER) issued the warning letter to Lus Essentials LLC.
- What CFR citations does this warning letter reference?
- The letter cites: FDA Warning Letter.
- Is the FDA warning letter to Lus Essentials LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lus-essentials-llc-728783-05142026.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for Lus Essentials LLC- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs/Misbranded: FDA Warning Letter to Lus Essentials LLC, May 14, 2026. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/lus-essentials-728783-2026-05-14
"Unapproved New Drugs/Misbranded: FDA Warning Letter to Lus Essentials LLC, May 14, 2026." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/lus-essentials-728783-2026-05-14.
Argus HQ Research. "Unapproved New Drugs/Misbranded: FDA Warning Letter to Lus Essentials LLC, May 14, 2026." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/lus-essentials-728783-2026-05-14.
@misc{argushq_argushq_ai_warning_letter_lus_essentials_728783_2026_05_14_2026,
title = {Unapproved New Drugs/Misbranded: FDA Warning Letter to Lus Essentials LLC, May 14, 2026},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/lus-essentials-728783-2026-05-14},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

